Table 4.

The unified Parkinson disease rating scale II improvement (UPDRS II at therapy initiation minus UPDRS II at 12 months follow-up) assessment by univariate analyses, then in relation with therapy in multivariate regression, adjusted for age, Parkinson disease duration, treatment duration, Hoehn and Yahr stage at the beginning, and in stratified multivariate analysis by Hoehn and Yahr stage.

	Unstratified analyses							Stratified by Hoehn & Yahr = 3			Stratified by Hoehn & Yahr = 4
	B	(95% CI)	P value	R2	B adjusted∗	(95% CI)	P value	B adjusted∗∗	(95% CI)	P value	B adjusted∗∗	(95% CI)	P value
Age (years)	−0.17	(−0.42–0.08)	.183	0.03	−0.12	(−0.24–0)	.042	0.003	(−0.08–0.09)	.941	−0.33	(−0.58–-0.08)	.011
Parkinson's disease duration (years)	0.52	(0.2–0.84)	.002	0.16	−0.02	(−0.22–0.18)	.845	−0.08	(−0.25–0.09)	.342	0.06	(−0.30–0.41)	.741
Treatment duration (years)	0.24	(−0.71–1.19)	.614	0.005	−0.21	(−0.72–0.3)	.422	−0.09	(−0.58–0.41)	.724	−0.21	(−1.04–0.62)	.605
Hoehn and Yahr stage at the beginning	9.29	(5.7–12.88)	<.001	0.32	0.33	(−2.46–3.11)	.815		–	–	–	–	–
Therapy (intrajejunal vs. oral)	15.17	(13.17–17.18)	<.001	0.80	15.19	(12.37–18.01)	<.001	15.4	(12.46–18.34)	<.001	14.72	(10.25–19.19)	<.001
Adjusted R2					0.81			0.8			0.74